Table 1.
Baseline patient characteristics
| Derivation cohort (n=124) | Validation cohort (n=66) | |||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Variable | HP cases (n=44) |
Non-HP ILD controls (n=80) |
p Value | HP cases (n=22) | Non-HP ILD controls (n=44) |
p Value |
| Age, years mean (SD) | 59.7 (10.8) | 56.8 (11.1) | 0.38 | 60.7 (15.4) | 63.1 (12.7) | 0.04 |
| Male sex, n (%) | 13 (29.6) | 41 (51.3) | 0.02 | 6 (27.3) | 22 (50.0) | 0.11 |
| Smoking history | ||||||
| Never smoker (%) | 21 (47.7) | 37 (46.9) | 1.00 | 15 (68.2) | 19 (43.2) | 0.07 |
| Ex-smoker (%) | 22 (50.0) | 41 (51.9) | 1.00 | 7 (31.8) | 25 (56.8) | 0.07 |
| Current smoker (%) | 1 (2.27) | 1 (1.27) | 1.00 | 0 (0.0) | 0 (0.0) | n/a |
| Pulmonary physiology | ||||||
| FVC, % predicted mean (SD) | 67.3 (17.4) | 70.3 (22.3) | 0.99 | 63.0 (17.1) | 78.5 (20.5) | 0.005 |
| FEV1, % predicted mean (SD) | 72.9 (18.4) | 73.8 (21.5) | 0.71 | 67.1 (15.5) | 83.6 (23.8) | 0.004 |
| FEV1/FVC mean (SD) | 0.82 (0.06) | 0.80 (0.09) | 0.35 | 0.83 (0.09) | 0.81 (0.08) | 0.38 |
| Selected exposure history | ||||||
| Bird (%) | 13 (29.6) | 9 (11.4) | 0.01 | 6 (27.3) | 3 (6.8) | 0.02 |
| Down (%) | 25 (56.8) | 29 (36.7) | 0.03 | 13 (59.1) | 22 (50.0) | 0.49 |
| Mould (%) | 11 (25.0) | 13 (16.4) | 0.34 | 6 (27.3) | 10 (22.7) | 0.76 |
| HRCT features | ||||||
| Mosaic perfusion (%) | 27 (61.4) | 17 (21.3) | <0.001 | 10 (45.5) | 5 (11.4) | <0.01 |
| Diffuse GGO predominance (%) | 12 (27.3) | 4 (5.0) | <0.001 | 4 (18.2) | 1 (2.3) | 0.02 |
| Fibrosis | 33 (75.0) | 62 (77.5) | 0.76 | 17 (77.3) | 39 (88.6) | 0.28 |
| Air trapping (%) | 19 (44.2) | 12 (15.2) | <0.001 | n/a | n/a | n/a |
GGO, ground-glass opacity; HP, hypersensitivity pneumonitis; HRCT, high-resolution CT; ILD, interstitial lung disease.